These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 30206299)

  • 1. An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
    Zhou Y; Mkrtchian S; Kumondai M; Hiratsuka M; Lauschke VM
    Pharmacogenomics J; 2019 Apr; 19(2):115-126. PubMed ID: 30206299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel machine learning-based approach for the computational functional assessment of pharmacogenomic variants.
    Pandi MT; Koromina M; Tsafaridis I; Patsilinakos S; Christoforou E; van der Spek PJ; Patrinos GP
    Hum Genomics; 2021 Aug; 15(1):51. PubMed ID: 34372920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
    Zhou Y; Pirmann S; Lauschke VM
    Pharmacogenomics J; 2024 May; 24(3):17. PubMed ID: 38802404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability.
    Zhou Y; Lauschke VM
    Clin Pharmacol Ther; 2021 Sep; 110(3):626-636. PubMed ID: 33998671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variant discovery using next-generation sequencing and its future role in pharmacogenetics.
    Russell LE; Schwarz UI
    Pharmacogenomics; 2020 May; 21(7):471-486. PubMed ID: 32338137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Next-Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes.
    Han SM; Park J; Lee JH; Lee SS; Kim H; Han H; Kim Y; Yi S; Cho JY; Jang IJ; Lee MG
    Clin Pharmacol Ther; 2017 Mar; 101(3):396-405. PubMed ID: 27727443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating rare genetic variants into pharmacogenetic drug response predictions.
    Ingelman-Sundberg M; Mkrtchian S; Zhou Y; Lauschke VM
    Hum Genomics; 2018 May; 12(1):26. PubMed ID: 29793534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions.
    Reisberg S; Krebs K; Lepamets M; Kals M; Mägi R; Metsalu K; Lauschke VM; Vilo J; Milani L
    Genet Med; 2019 Jun; 21(6):1345-1354. PubMed ID: 30327539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of whole-genome sequencing-based pharmacogenetic profiling.
    Caspar SM; Schneider T; Stoll P; Meienberg J; Matyas G
    Pharmacogenomics; 2021 Feb; 22(3):177-190. PubMed ID: 33517770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
    Hachad H; Ramsey LB; Scott SA
    Clin Pharmacol Ther; 2019 Aug; 106(2):298-301. PubMed ID: 31162629
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
    Goljan E; Abouelhoda M; ElKalioby MM; Jabaan A; Alghithi N; Meyer BF; Monies D
    PLoS One; 2022; 17(1):e0263137. PubMed ID: 35089958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying Multiplex Assays to Understand Variation in Pharmacogenes.
    Chiasson M; Dunham MJ; Rettie AE; Fowler DM
    Clin Pharmacol Ther; 2019 Aug; 106(2):290-294. PubMed ID: 31145826
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of population-specific pharmacogenomic variants using next-generation sequencing data.
    Ahn E; Park T
    Sci Rep; 2017 Sep; 7(1):8416. PubMed ID: 28871186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing.
    Suzuki O; Dong OM; Howard RM; Wiltshire T
    Pharmacogenomics; 2019 Sep; 20(14):1005-1020. PubMed ID: 31559919
    [No Abstract]   [Full Text] [Related]  

  • 16. Requirements for comprehensive pharmacogenetic genotyping platforms.
    Lauschke VM; Ingelman-Sundberg M
    Pharmacogenomics; 2016 Jun; 17(8):917-24. PubMed ID: 27248710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic testing in oncology: a Brazilian perspective.
    Suarez-Kurtz G
    Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e565s. PubMed ID: 30328952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
    Ng D; Hong CS; Singh LN; Johnston JJ; Mullikin JC; Biesecker LG
    Genet Med; 2017 Mar; 19(3):357-361. PubMed ID: 27537706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
    Lauschke VM; Ingelman-Sundberg M
    Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population.
    Yu MHC; Chan MCY; Chung CCY; Li AWT; Yip CYW; Mak CCY; Chau JFT; Lee M; Fung JLF; Tsang MHY; Chan JCK; Wong WHS; Yang J; Chui WCM; Chung PHY; Yang W; Lee SL; Chan GCF; Tam PKH; Lau YL; Tang CSM; Yeung KS; Chung BHY
    PLoS Genet; 2021 Feb; 17(2):e1009323. PubMed ID: 33600428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.